Vaxcyte, Inc. $PCVX Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 57.7% during the first quarter, HoldingsChannel reports. The institutional investor owned 32,212 shares of the company’s stock after acquiring an additional 11,783 shares during the period. SG Americas Securities LLC’s holdings in Vaxcyte were worth $1,872,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its position in shares of Vaxcyte by 30.6% during the third quarter. JPMorgan Chase & Co. now owns 1,565,036 shares of the company’s stock worth $56,373,000 after purchasing an additional 366,266 shares in the last quarter. Pivotal bioVenture Partners Investment Advisor LLC lifted its holdings in shares of Vaxcyte by 5.2% in the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,372,425 shares of the company’s stock valued at $49,435,000 after purchasing an additional 67,300 shares during the last quarter. HighVista Strategies LLC boosted its position in shares of Vaxcyte by 159.4% in the 3rd quarter. HighVista Strategies LLC now owns 86,802 shares of the company’s stock valued at $3,127,000 after purchasing an additional 53,345 shares during the period. Bridgefront Capital LLC boosted its position in shares of Vaxcyte by 127.2% in the 3rd quarter. Bridgefront Capital LLC now owns 24,325 shares of the company’s stock valued at $876,000 after purchasing an additional 13,617 shares during the period. Finally, NEXTBio Capital Management LP purchased a new position in Vaxcyte during the 4th quarter worth approximately $4,406,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Vaxcyte news, CEO Grant Pickering sold 22,461 shares of the company’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the completion of the transaction, the chief executive officer owned 474,703 shares in the company, valued at approximately $24,921,907.50. This represents a 4.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the firm’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total transaction of $180,000.00. Following the completion of the sale, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. This trade represents a 9.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 66,198 shares of company stock valued at $3,571,655. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Stock Up 4.1%

PCVX opened at $58.39 on Friday. The business has a 50 day moving average price of $52.26 and a two-hundred day moving average price of $53.38. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The company has a market cap of $8.43 billion, a PE ratio of -8.49 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter last year, the business earned ($1.04) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Finally, Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Vaxcyte has an average rating of “Moderate Buy” and an average target price of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.